Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to PCV13 with concomitant hepatitis A vaccination in adults
2012-003484-22Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of pneumococcal 13-valent conjugate vaccine, Hepatitis A virus vaccine and Epaxal Junior in pneumococcal disease and hepatitis A (HAV) (3 arms), sponsored by Helsinki University Hospital. Primary endpoints: Pneumococcal serotype-specific serum IgG antibodies and Opsonophagocytic activity against pneumococcal serotypes. Started Aug 2012; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccineHepatitis A virus vaccineEpaxal Junior
03
Conditions
pneumococcal diseasehepatitis A (HAV)
Beyond the preview
Go deeper on 2012-003484-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003484-22.